Compare MSBI & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MSBI | ALLO |
|---|---|---|
| Founded | 1881 | 2017 |
| Country | United States | United States |
| Employees | 861 | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 466.7M | 539.4M |
| IPO Year | N/A | 2018 |
| Metric | MSBI | ALLO |
|---|---|---|
| Price | $23.99 | $3.14 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 12 |
| Target Price | ★ $22.83 | $8.73 |
| AVG Volume (30 Days) | 115.3K | ★ 7.6M |
| Earning Date | 04-23-2026 | 05-12-2026 |
| Dividend Yield | ★ 5.34% | N/A |
| EPS Growth | N/A | ★ 34.09 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $18.41 | N/A |
| Revenue Next Year | $2.07 | $144,130.60 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $14.24 | $0.86 |
| 52 Week High | $24.72 | $4.46 |
| Indicator | MSBI | ALLO |
|---|---|---|
| Relative Strength Index (RSI) | 65.50 | 66.63 |
| Support Level | $20.81 | $1.10 |
| Resistance Level | $24.41 | N/A |
| Average True Range (ATR) | 0.61 | 0.30 |
| MACD | 0.28 | 0.06 |
| Stochastic Oscillator | 77.86 | 43.83 |
Midland States Bancorp Inc is a diversified financial holding company. The company provides a full range of commercial and consumer banking products and services, business equipment financing, merchant credit card services, trust and investment management, and insurance and financial planning services. The Banking segment, which generates the majority of the revenue, provides financial products and services to consumers and businesses, including commercial, commercial real estate, mortgage, and other consumer loan products; commercial equipment financing, etc. The Wealth Management segment consists of trust and fiduciary services, brokerage, and retirement planning services. The Corporate segment includes the holding company's financing and investment activities, administrative expenses.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.